experimental group:Aumolertinib as postoperative adjuvant therapy
Sponsors
The First Affiliated Hospital of Sun Yat-sen University
Conditions
Lung Cancernon-small cell lung cancer (NSCLC)
Phase 4
A multicenter, open-label, single-arm clinical study of Aumolertinib mesylate as postoperative adjuvant treatment for patients with EGFRm positive stage IB and pure solid stage IA2-3 invasive Non-Small Cell Lung Cancer
Active, not recruitingChiCTR2200062887
Start: 2022-09-01Updated: 2023-04-12
A multicenter, open-label, single-arm clinical study of Aumolertinib mesylate as postoperative adjuvant treatment for patients with EGFRm positive stage IB and pure solid stage IA2-3 invasive non-small cell lung cancer
Active, not recruitingChiCTR2200063184
Start: 2022-09-01Updated: 2023-04-12